Drug intelligence / Profile preview

H5 Flu IMP 11

Development stage: Unknown
Lead developer: Sanofi Pasteur
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

H5 Flu IMP 11 is an investigational mRNA-based vaccine candidate developed by Sanofi for the prevention of avian influenza caused by the H5N1 subtype of the Influenza A virus. It is one of several experimental formulations being evaluated in a Phase 1 clinical trial (NCT06095908) designed to identify the optimal safety and immunogenicity profile of vaccines encoding the hemagglutinin (H5) antigen. The vaccine utilizes mRNA technology to instruct host cells to express the H5 protein, a key surface glycoprotein of the influenza virus, thereby eliciting a targeted immune response. It is administered as a suspension for intramuscular injection.

Other names: IMP 11-Sanofi-respiratory syncytial virus-influenza A(H5N1)

Targets

HA (Hemagglutinin)

Beyond the preview

Go deeper on H5 Flu IMP 11.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on H5 Flu IMP 11.

Explore the full profile